Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Glia. 2010 Sep 27;59(1):1–13. doi: 10.1002/glia.21071

Figure 1. BzATP-induced attenuation of LPS-induced iNOS/NO production in murine microglia occurs within 2 hours and is sensitive to P2X7 antagonists.

Figure 1

(A) BzATP treatment attenuates LPS-stimulated NO production. N9 and primary murine microglia were treated with vehicle (250 mM Hepes), LPS (100 ng/mL) or co-treated with LPS+ BzATP (150 μM) for 16-20 hours. Nitrite levels were measured in the medium the following day. **p< 0.01 vs. vehicle treatment. (B) LPS-induced iNOS mRNA levels are dose-dependently reduced by BzATP treatment. The data are graphed as percent expression relative to LPS treatment. **p<0.01 vs. LPS treatment. (C) LPS-induced iNOS mRNA levels are reduced by BzATP, an effect that is reversed by the novel P2X7 antagonist A-438079. **p<0.01 vs. LPS treatment. (D) BzATP reduces LPS-stimulated NO production within 1-2 hours after treatment. Cells were treated with LPS alone (hatched bar), co-treated with LPS+BzATP (black bar), or pre-treated with BzATP for times indicated (3rd through 7th bars, respectively), prior to medium washout and stimulation with LPS. All treatments were performed in triplicate and the means ± SEM for the data shown are representative of 4-7 independent experiments. **p<0.01 vs. LPS treatment alone.